Delayed Quote. Delayed  - 05/14 11:35:04 am
33.75EUR +0.33%

PRESS RELEASE: Evotec SE to announce results for the first quarter 2021 on 11 May 2021

05/04/2021 | 05:32am
DGAP-News: Evotec SE / Key word(s): Miscellaneous 
Evotec SE to announce results for the first quarter 2021 on 11 May 2021 
2021-05-04 / 11:30 
The issuer is solely responsible for the content of this announcement. 
Hamburg, Germany, 04 May 2021: 
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) will announce its financial results for the 
first quarter of 2021 on Tuesday, 11 May 2021. 
The Company is going to hold a conference call to discuss the results as well as to provide an update on its 
performance. The conference call will be held in English. 
Conference call details 
Date: Tuesday, 11 May 2021 
Time: 02.00 pm CET (08.00 am EST, 01.00 pm GMT) 
From Germany: +49 69 20 17 44 220 
From France: +33 170 709 502 
From Italy: +39 023 600 6663 
From UK: +44 20 3009 2470 
From USA: +1 877 423 0830 
Access Code: 94660964# 
A simultaneous slide presentation for participants dialling in via phone is available at https://www.webcast-eqs.com/ 
Webcast details 
To join the audio webcast and to access the presentation slides you will find a link on our homepage www.evotec.com 
shortly before the event. 
A replay of the conference call will be available for seven days and can be accessed from Germany by dialling +49 69 
201744221, from UK by dialling +44 20 3364 5150 and from USA by dialling +1 (844) 307-9362. 
The access code is 315614523#. The on-demand version of the webcast will be available on our website: https:// 
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative 
product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and 
venture capitalists. We operate worldwide and our more than 3,700 employees provide the highest quality stand-alone and 
integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the 
industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has 
established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies 
as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and 
complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare 
diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of more than 100 co-owned 
product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple 
long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo 
Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us 
on Twitter @Evotec. 
Information set forth in this press release contains forward-looking statements, which involve a number of risks and 
uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this 
press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of 
risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ 
materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or 
undertaking to release publicly any updates or revisions to any such statements to reflect any change in our 
expectations or any change in events, conditions or circumstances on which any such statement is based. 
2021-05-04 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
Language:     English 
Company:      Evotec SE 
              Manfred Eigen Campus / Essener Bogen 7 
              22419 Hamburg 
Phone:        +49 (0)40 560 81-0 
Fax:          +49 (0)40 560 81-222 
E-mail:       info@evotec.com 
Internet:     www.evotec.com 
ISIN:         DE0005664809 
WKN:          566480 
Indices:      MDAX, TecDAX 
Listed:       Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1192318 
End of News   DGAP News Service 

1192318 2021-05-04

Image link: 

(END) Dow Jones Newswires

May 04, 2021 05:31 ET (09:31 GMT)

Copier lien
All news about EVOTEC SE
3d ago
4d ago
4d ago
4d ago
5d ago